Estelle Ricoux
Co-Founder & Director - Strategy & Design FIRM
Estelle has 15 years experience partnering with clients and leading teams to improve customer and employee experiences. She combines a holistic service design practice with product methodologies to bring focus on business goals and key metrics. She leads Firm’s design teams, assessing current experiences and operations, crafting visions for future experiences and products, and guiding in the design and delivery, helping companies adopt new approaches and ways of working in the process
Seminars
TATs represent an exciting and fast-evolving class of targeted therapies with the potential for high therapeutic impact due to the potent, short-range cytotoxicity of alpha particles. While clinical interest and investment in these agents are growing rapidly, bringing up-and-coming alpha emitters such as 211-At and 212-Pb from early discovery into broad clinical use remains challenging.
This workshop will provide an integrated analysis from scientific foundations through to real-world supply chain considerations, addressing the technical, logistical, and commercial hurdles that must be overcome to enable the future success of TATs.
- Explore the radiophysical properties of promising alpha emitters including astatine-211 and lead-212
- Assess current and emerging industrial-scale production approaches – from cyclotron networks for 211-At to thorium-228-based generator systems for 212-Pb
- Identify challenges in logistics due to short half-lives and regulatory/licensing constraints, and best practices for supply preparedness
- Review the evolving market dynamics for alpha emitters, investment trends, and competitive positioning in the context of a growing radioligand therapy space
–
Outcome – Whitepaper on Alpha Supply Chain Roadmap-collaborative draft outlining strategic recommendations for scalable production and reliable distribution of 211-At and 212-Pb, including infrastructure gaps and potential solutions.
